NCT05923008View on ClinicalTrials.gov

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

182

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

October 31, 2026

Conditions

Solid Tumor

Interventions

DRUG

IBI130

Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.

Trial Locations (1)

4575

RECRUITING

Sunshine Coast University, Birtinya

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05923008 - A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter